Decision on Norwegian PET (positron emission tomography) delayed
This article was originally published in Clinica
Although the cost of introducing PET to Norway would be relatively high, its health benefits are obvious, says the leader of the Norwegian health and social committee, John Alvheim. He questioned why Norway's Scandinavian partners, Sweden and Denmark, had been using PET for some 20 years, but Norwegian cancer patients were not given access to the technology. "The number of people we could treat with this equipment would be several times the amount we currently do, using CT and MRI," said Mr Alvheim.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.